Analytical Data
-
基因名
ALK
- Application
-
别名
ALK；ALK tyrosine kinase receptor
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UM73
-
表达区间
1060-1620aa
-
氨基酸序列
RRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLK EVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQ DELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLR ETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTC PGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSK TDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVY RIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEE KVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAA EISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGS WFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEP SSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTIL KSKNSMNQPGP
-
分子量
90 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of Anaplastic Lymphoma Kinase (ALK) recombinant proteins has gained significant attention in recent years due to their critical roles in various malignancies, particularly in non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). ALK is a receptor tyrosine kinase that, when aberrantly expressed or mutated, leads to uncontrolled cell growth and tumorigenesis. Research has identified several ALK fusion proteins, resulting from chromosomal translocations, which are particularly prevalent in certain cancers. These fusions often result in constitutively active ALK proteins, leading to oncogenic signaling pathways that promote cancer development. The discovery of these ALK rearrangements has not only provided insights into the molecular mechanisms underlying these cancers but has also paved the way for targeted therapies, such as crizotinib and other ALK inhibitors. The development of recombinant ALK proteins is essential for elucidating the structural and functional aspects of these fusion proteins, as well as for high-throughput screening of potential inhibitors. Furthermore, these recombinant proteins serve as valuable tools in preclinical studies to investigate patient responses to ALK-targeted therapies, supporting personalized treatment approaches. As our understanding of ALK's role in cancer biology continues to evolve, ongoing research into ALK recombinant proteins remains crucial for advancing therapeutic strategies and improving outcomes for patients with ALK-positive malignancies.
